Den Otter W - Search Results

1

Role of marker lesion when applying intravesical instillations of IL-2 for non-muscle-invasive bladder cancer comparison of the therapeutic effects in two pilot studies.

Den Otter W, Van Moorselaar RJ, Jacobs JJ, Haar RT, Koten JW, Dobrowolski Z, Lipczynski W, Pašukonienė V, Characiejus D, Jankevičius F, Eidukevičius R, De Reijke TM. Den Otter W, et al. Anticancer Res. 2013 May;33(5):2099-105. Anticancer Res. 2013. PMID: 23645761

2

Prognostic significance of peripheral blood CD8highCD57+ lymphocytes in bladder carcinoma patients after intravesical IL-2.

Characiejus D, Pasukoniene V, Jacobs JJ, Eidukevicius R, Jankevicius F, Dobrovolskiene N, Mauricas M, Van Moorselaar RJ, Den Otter W. Characiejus D, et al. Among authors: den otter w. Anticancer Res. 2011 Feb;31(2):699-703. Anticancer Res. 2011. PMID: 21378359

3

Treatment of transmissible venereal tumors in dogs with intratumoral interleukin-2 (IL-2). A pilot study.

Den Otter W, Hack M, Jacobs JJ, Tan JF, Rozendaal L, Van Moorselaar RJ. Den Otter W, et al. Anticancer Res. 2015 Feb;35(2):713-7. Anticancer Res. 2015. PMID: 25667450

4

Effective Treatment of Transmissible Venereal Tumors in Dogs with Vincristine and IL2.

DEN Otter W, Hack M, Jacobs JJ, Tan JF, Rozendaal L, VAN Moorselaar RJ. DEN Otter W, et al. Anticancer Res. 2015 Jun;35(6):3385-91. Anticancer Res. 2015. PMID: 26026099

5

Treatment of stage III-IV nasopharyngeal carcinomas by external beam irradiation and local low doses of IL-2.

Jacobs JJ, Hordijk GJ, Jürgenliemk-Schulz IM, Terhaard CH, Koten JW, Battermann JJ, Den Otter W. Jacobs JJ, et al. Among authors: den otter w. Cancer Immunol Immunother. 2005 Aug;54(8):792-8. doi: 10.1007/s00262-004-0641-6. Epub 2004 Dec 31. Cancer Immunol Immunother. 2005. PMID: 15627211 Free PMC article. Clinical Trial.

6

Local therapy of cancer with free IL-2.

Den Otter W, Jacobs JJ, Battermann JJ, Hordijk GJ, Krastev Z, Moiseeva EV, Stewart RJ, Ziekman PG, Koten JW. Den Otter W, et al. Cancer Immunol Immunother. 2008 Jul;57(7):931-50. doi: 10.1007/s00262-008-0455-z. Cancer Immunol Immunother. 2008. PMID: 18256831 Free PMC article.

7

Prediction of response in cancer immunotherapy.

Characiejus D, Jacobs JJ, Pašukonienė V, Kazlauskaitė N, Danilevičiūtė V, Mauricas M, Den Otter W. Characiejus D, et al. Among authors: den otter w. Anticancer Res. 2011 Feb;31(2):639-47. Anticancer Res. 2011. PMID: 21378350 Review.

8

Inefficacy of therapeutic cancer vaccines and proposed improvements. Casus of prostate cancer.

Jacobs JJ, Snackey C, Geldof AA, Characiejus D, Van Moorselaar RJ, Den Otter W. Jacobs JJ, et al. Among authors: den otter w. Anticancer Res. 2014 Jun;34(6):2689-700. Anticancer Res. 2014. PMID: 24922629 Review.

9

Intravesical interleukin-2 in T1 papillary bladder carcinoma: regression of marker lesion in 8 of 10 patients.

Den Otter W, Dobrowolski Z, Bugajski A, Papla B, Van Der Meijden AP, Koten JW, Boon TA, Siedlar M, Zembala M. Den Otter W, et al. J Urol. 1998 Apr;159(4):1183-6. doi: 10.1097/00005392-199804000-00021. J Urol. 1998. PMID: 9507828 Clinical Trial.

10

What is cancer? Theories on carcinogenesis.

Den Otter W, Root-Bernstein R, Koten JW. Den Otter W, et al. Anticancer Res. 1999 Nov-Dec;19(6A):4601-2. Anticancer Res. 1999. PMID: 10697580 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

297 results

Search Page